Arrowhead Pharmaceuticals, Inc. (XETR:HDP1) Financings
Financings
| Raise | Date |
|---|---|
| 0.00% convertible senior notes due 2032 Closed: US$625M raised · J.P. Morgan +4 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets Use of proceeds: About $42.8 million for capped call transactions; remainder for general corporate purposes incl. R&D, clinical trials and commercial launch preparation | Feb 5, 2026 |
| Public offering of common stock and pre-funded warrants Closed: US$200M raised · US$64.5 a share · Jefferies +4 Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), BofA Securities, Piper Sandler, RBC Capital Markets Use of proceeds: General corporate purposes incl. working capital, R&D, clinical trials and commercial launch preparation; may prepay Sixth Street loans | Feb 5, 2026 |
| Strategic investment of common stock Closed: US$325M raised · US$27.25 a share Buyers: Sarepta ($325 million of Arrowhead common stock at $27.25 per share) | Oct 21, 2025 |
| Strategic investment of common stock Closed: US$325M raised · US$27.25 a share Buyers: Sarepta Therapeutics ($325 million equity investment priced at $27.2507); Sarepta ($325 million of Arrowhead common stock at $27.25 per share) | Feb 10, 2025 |